US 11,981,643 B1
Oxoimidazolidine derivatives as anti-tubercular agents
Katharigatta N. Venugopala, Al-Ahsa (SA); Pran Kishore Deb, Ranchi (IN); Melendran Pillay, Durban (ZA); Nefisath P, Ujire (IN); Mohamed A. Morsy, Al-Ahsa (SA); Shashiprabha S, Ujire (IN); Jagadeesh Prasad Dasappa, Mangalagangothri (IN); and Rashmi Venugopala, Durban (ZA)
Assigned to KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed by KING FAISAL UNIVERSITY, Al-Ahsa (SA)
Filed on Oct. 2, 2023, as Appl. No. 18/375,672.
Int. Cl. A61P 31/06 (2006.01); C07D 233/96 (2006.01); C07D 405/06 (2006.01)
CPC C07D 233/96 (2013.01) [A61P 31/06 (2018.01); C07D 405/06 (2013.01)] 14 Claims
 
1. A method of treating tuberculosis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
X is selected from the group consisting of O and S;
R is one or more halogens;
n is 1, 2, or 3; and
R1 is selected from the group consisting of an optionally substituted phenyl and an optionally substituted furanyl.